EGLN1 and B-cell chronic lymphocytic leukemia: Our study suggests that the EGLN1 gene may serve as a therapeutic target for CLL and that the HIF-PH inhibitor molidustat may inhibit CLL cell proliferation by inhibiting the ribosome biogenesis pathway.